STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[144] PRECIGEN, INC. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary

Precigen, Inc. (PGEN) Form 144 notifies the market of a proposed sale of 252 common shares on Nasdaq with an aggregate market value of $970, against 297,972,920 shares outstanding. The filer reports acquiring 3,112,507 shares on 07/03/2018 in a public offering for cash.

The filing also discloses that Kapital Joe, LLC (Randal J. Kirk as agent) sold 1,403,360 common shares on 09/18/2025 for gross proceeds of $5,422,348. The signer certifies no undisclosed material adverse information and attests to the accuracy of the notice.

Positive
  • Disclosure compliance: Form 144 properly lists the class, acquisition details, and recent sales, supporting regulatory transparency
  • Long-held shares: The securities to be sold trace to a 07/03/2018 public offering, showing acquisition provenance
Negative
  • Recent affiliate sale: Kapital Joe, LLC sold 1,403,360 shares on 09/18/2025 for $5,422,348, indicating notable insider/affiliate liquidity

Insights

TL;DR: Routine Rule 144 notice; small proposed sale and a recent 1.4M-share disposition reported, reflecting insider/affiliate liquidity, not clearly material to valuation.

The filing records a proposed sale of 252 shares (aggregate value $970) under Rule 144 and documents a recent larger disposition by Kapital Joe, LLC of 1,403,360 shares for $5.42 million. For a company with ~298 million shares outstanding, the recent sale equals roughly 0.47% of the outstanding float, indicating insider/affiliate liquidity but not necessarily a material dilution event. The filing appears procedurally compliant and provides acquisition provenance dating to a 2018 public offering.

TL;DR: Disclosure is consistent with Rule 144 requirements; signer affirms no undisclosed material information.

The document follows Rule 144 format by identifying the class, intended sale amount, provenance of the shares, and recent sales by related parties. The signature statement affirms the absence of undisclosed material information, which is standard. The recent sale by a related entity is disclosed, enabling investor transparency about insider/affiliate transactions.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does Precigen's (PGEN) Form 144 disclose about the proposed sale?

The Form 144 states a proposed sale of 252 common shares with an aggregate market value of $970 on Nasdaq, against 297,972,920 shares outstanding.

Who acquired the shares being offered and when?

The shares were acquired in a public offering on 07/03/2018, totaling 3,112,507 shares acquired for cash.

Were there any recent related-party sales disclosed in the filing?

Yes. Kapital Joe, LLC (Randal J. Kirk as agent) sold 1,403,360 common shares on 09/18/2025 for gross proceeds of $5,422,348.

Does the filer assert there is undisclosed material information?

No. By signing the notice, the person represents they do not know any material adverse information about the issuer that has not been publicly disclosed.

On which exchange are the shares planned to be sold?

The filing indicates the sale is planned on Nasdaq.
Precigen Inc

NASDAQ:PGEN

PGEN Rankings

PGEN Latest News

PGEN Latest SEC Filings

PGEN Stock Data

1.38B
305.38M
10.47%
66.81%
12.13%
Biotechnology
Pharmaceutical Preparations
Link
United States
GERMANTOWN